• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Metabolic tumour volume and response to therapy in diffuse large B-cell lymphoma.

作者信息

Campiotti Leonardo, Suter Matteo B, De Palma Diego, Proserpio Ilaria, Uccella Silvia, Squizzato Alessandro

机构信息

Department of Medicine and Surgery, Unit of Internal Medicine, University of Insubria, Varese, Italy.

Medical Oncology, Ospedale di Circolo e Fondazione Macchi, ASST Sette Laghi, Varese, Italy.

出版信息

Hematol Oncol. 2019 Aug;37(3):308-309. doi: 10.1002/hon.2612. Epub 2019 Apr 26.

DOI:10.1002/hon.2612
PMID:30933368
Abstract
摘要

相似文献

1
Metabolic tumour volume and response to therapy in diffuse large B-cell lymphoma.弥漫性大B细胞淋巴瘤的代谢肿瘤体积与治疗反应
Hematol Oncol. 2019 Aug;37(3):308-309. doi: 10.1002/hon.2612. Epub 2019 Apr 26.
2
High rate of event-free survival at 24 months with everolimus/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance).依维莫司联合RCHOP方案治疗初治弥漫性大B细胞淋巴瘤24个月时无事件生存率高：NCCTG N1085（联盟）的更新结果
Blood Cancer J. 2017 Jun 23;7(6):e576. doi: 10.1038/bcj.2017.57.
3
Results of a large retrospective analysis of the effect of intended dose intensity of R-CHOP on outcome in a cohort of consecutive, unselected elderly patients with de novo diffuse large B cell lymphoma.一项针对连续入选的、未经筛选的老年初发弥漫性大B细胞淋巴瘤患者队列，对R-CHOP计划剂量强度对预后影响的大型回顾性分析结果。
Br J Haematol. 2016 May;173(3):487-91. doi: 10.1111/bjh.13619. Epub 2015 Jul 29.
4
Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.在预后不良的未经治疗的弥漫性大 B 细胞非霍奇金淋巴瘤的非常老年患者中，使用利妥昔单抗的剂量调整的输注环磷酰胺、多柔比星、长春新碱和泼尼松化疗的活性和安全性。
Cancer. 2011 Mar 1;117(5):964-73. doi: 10.1002/cncr.25582. Epub 2010 Oct 19.
5
Comparison of R-CVP with R-CHOP for very elderly patients aged 80 or over with diffuse large B cell lymphoma.利妥昔单抗联合环磷酰胺、长春新碱和泼尼松（R-CVP）与利妥昔单抗联合环磷酰胺、多柔比星、长春新碱和泼尼松（R-CHOP）用于80岁及以上弥漫性大B细胞淋巴瘤老年患者的比较。
Ann Hematol. 2017 Jul;96(7):1225-1226. doi: 10.1007/s00277-017-3017-7. Epub 2017 May 15.
6
Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.利妥昔单抗联合MACOP-B或VACOP-B方案及放疗治疗原发性纵隔大B细胞淋巴瘤：一项回顾性研究
Clin Lymphoma Myeloma. 2009 Oct;9(5):381-5. doi: 10.3816/CLM.2009.n.074.
7
Impact of body mass index on incidence of febrile neutropenia and treatment-related mortality in United States veterans with diffuse large B-cell lymphoma receiving rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone.体重指数对接受利妥昔单抗、环磷酰胺、阿霉素、长春新碱、泼尼松治疗的美国弥漫性大B细胞淋巴瘤退伍军人发热性中性粒细胞减少症发病率及治疗相关死亡率的影响
Br J Haematol. 2014 Dec;167(5):699-702. doi: 10.1111/bjh.13026. Epub 2014 Jul 15.
8
Efficacy and tolerability of rituximab and reduced-dose cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy for elderly patient with diffuse large B-cell lymphoma.利妥昔单抗与低剂量环磷酰胺、阿霉素、长春新碱和泼尼松龙联合治疗老年弥漫性大B细胞淋巴瘤的疗效及耐受性
Hematology. 2019 Dec;24(1):52-59. doi: 10.1080/10245332.2018.1509461. Epub 2018 Aug 11.
9
Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.利妥昔单抗密集化疗联合或不联合大剂量化疗和自体干细胞移植治疗高危弥漫性大 B 细胞淋巴瘤（DLCL04）：一项多中心、开放标签、随机、对照、3 期研究的最终结果。
Lancet Oncol. 2017 Aug;18(8):1076-1088. doi: 10.1016/S1470-2045(17)30444-8. Epub 2017 Jun 28.
10
Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi.来那度胺联合环磷酰胺、多柔比星、长春新碱、泼尼松和利妥昔单抗治疗未经治疗的老年弥漫性大 B 细胞淋巴瘤患者安全有效：一项由意大利淋巴瘤基金会开展的 I 期研究。
Haematologica. 2013 Nov;98(11):1732-8. doi: 10.3324/haematol.2013.085134. Epub 2013 Jun 28.